Neurogene Inc. financial data

Symbol
NGNE on Nasdaq
Industry
Pharmaceutical Preparations
Location
535 W 24 Th Street, 5 Th Floor, New York, NY
Fiscal year end
December 31
Former names
Neoleukin Therapeutics, Inc. (to 12/6/2023), AQUINOX PHARMACEUTICALS, INC (to 8/12/2019), AQUINOX PHARMACEUTICALS (USA) INC (to 12/24/2013)
Latest financial report
10-Q - Q3 2024 - Nov 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.06K % -23.9%
Debt-to-equity 17.4 %
Return On Equity -25.9 % -185%
Return On Assets -22 % +56.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.9M shares +58.1%
Common Stock, Shares, Outstanding 13M shares +47.8%
Entity Public Float 33.4M USD -7.62%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 17M shares +3699%
Weighted Average Number of Shares Outstanding, Diluted 17M shares +3699%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 57.8M USD +18.9%
General and Administrative Expense 19M USD +383%
Operating Income (Loss) -75.8M USD -44.4%
Nonoperating Income (Expense) -24K USD +36.8%
Net Income (Loss) Attributable to Parent -42M USD +15.7%
Earnings Per Share, Basic 24.5 USD/shares +96.4%
Earnings Per Share, Diluted -0.35 USD/shares +99.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 66.6M USD +164%
Other Assets, Current 1.6M USD +15.4%
Assets, Current 144M USD +79.8%
Property, Plant and Equipment, Net 16.1M USD +3220%
Operating Lease, Right-of-Use Asset 3.19M USD -63.2%
Other Assets, Noncurrent 789K USD +50.6%
Assets 164M USD +83.2%
Accounts Payable, Current 1.68M USD
Employee-related Liabilities, Current 3.43M USD
Accrued Liabilities, Current 10.4M USD
Liabilities, Current 15.8M USD +203%
Operating Lease, Liability, Noncurrent 10.2M USD +11.3%
Other Liabilities, Noncurrent 51K USD
Liabilities 26.7M USD +86.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -243M USD +48.5%
Stockholders' Equity Attributable to Parent 137M USD
Liabilities and Equity 164M USD +83.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.7M USD -59.7%
Net Cash Provided by (Used in) Financing Activities -6.52M USD -6197%
Net Cash Provided by (Used in) Investing Activities 29.9M USD
Common Stock, Shares Authorized 450M shares +2150%
Common Stock, Shares, Issued 13M shares +47.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.76M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 67M USD +47%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3K USD +50%
Deferred Tax Assets, Valuation Allowance 98.9M USD +159%
Deferred Tax Assets, Gross 99.9M USD +154%
Operating Lease, Liability 13M USD
Payments to Acquire Property, Plant, and Equipment 65K USD +124%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.2M USD +65.5%
Lessee, Operating Lease, Liability, to be Paid 15.8M USD
Property, Plant and Equipment, Gross 26.5M USD
Operating Lease, Liability, Current 2.86M USD +84.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.7M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.99M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.78M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.24M USD
Deferred Tax Assets, Operating Loss Carryforwards 60.3M USD +139%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares +900%
Unrecognized Tax Benefits 2.61M USD +136%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.29M USD
Operating Lease, Payments 1.31M USD
Additional Paid in Capital 380M USD -30.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.26M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 949K USD -18.5%
Share-based Payment Arrangement, Expense 6.19M USD +541%
Interest Expense 3K USD +50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%